Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
Website: https://www.novartis.com/
2102 articles with Novartis
-
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
-
Greece’s Health Minister Thanos Plevris announced plans to sue Novartis over what he alleges are illegal practices. In addition to demanding compensation, the country is implementing a three-point plan.
-
Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
-
A recent research report points to the CDMO market heating up. P&S projected the global biologics CDMO market would hit $31.839 million by 2030.
-
With regulatory approvals beginning to break through, attendees at ISCT's annual meeting set out along the translational pathway. Organizers shared their findings with BioSpace.
-
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Novartis announced on Thursday that it will be temporarily and voluntarily suspending the production of its cancer therapeutics Lutathera and Pluvicto at facilities in Italy and New Jersey.
-
Intellia’s first-quarter financial conference call and report focused on the ongoing Phase I trial of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy patients.
-
Novartis’ Kisqali (ribociclib) plus the chemotherapy drug fulvestrant provided some post-menopausal breast cancer patients’ survival benefit of more than five-and-a-half years of life.
-
BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.
-
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
-
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.
-
BeiGene, Novartis Drug Tislelizumab Demonstrates Strong Survival Benefit in Esophageal Cancer
4/27/2022
BeiGene's candidate drug tislelizumab for cancer succeeded in meeting the primary endpoint of overall survival in a global Phase III trial. Learn more about it here. -
Novartis’ Sandoz business unit saw a strong financial performance in the first quarter of 2022, with overall sales growth of 8%, mostly outside of the United States.
-
AbbVie, Novartis, Pfizer and other biopharma companies are ramping up support to Ukraine in the face of the continuing Russian invasion.
-
The company brings to the arena bioengineered tissues that repair, restore or replace an organ or tissue functioning, called Tissue Therapeutics.
-
The U.S. FDA's Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
-
The data collected from the cut-off demonstrates that patients can maintain an average of 9.6 months without disease progression after the initial dosage of the tislelizumab-chemotherapy treatment.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.